HeartSciences Inc (HSCS) — Titan Protect Analysis

HSCS

HeartSciences Inc

Healthcare · ·

$1.94

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$7M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.73

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-382.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+415% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About HeartSciences Inc

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventi

https://heartsciences.com

Country: United States Employees: 15 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.110

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0260

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.561

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-40.0%

Historical annualised return based on price data

Max Drawdown

-71.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.04

Significantly more volatile than the market

52W High

$6.47

70% below the year high

52W Low

$1.63

19% above the year low

Avg Volume

23,793

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.49

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

145.81

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

57.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-89,939.6%

Profit from core operations before interest and tax

Free Cash Flow

$-4,213,324

Negative — the business is spending more than it generates

Revenue (TTM)

$8,669

Total revenue over the last 12 months

Net Income

$-8,485,301

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$10.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go